GT Biopharma Appoints New Member to its Board of Directors

SAN FRANCISCO, CALIFORNIA, May 14, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE^® natural killer (NK) cell engager platform, today announced the appointment of Hilary Kramer to its Board of Directors. Mrs. Kramer will be replacing current board member Bruce Wendel, who is resigning his position.

Read more at globenewswire.com